Company intelligence
Nautilus Biotechnology
Delivering on the Promise of the Human Proteome
About Nautilus Biotechnology
Born from the founders’ recognition that their diverse but complementary skills and experiences would enable them to successfully address challenges that others had not, Nautilus (Nasdaq: NAUT) set about solving a vexing problem: how to bring true proteomics to the world in a way that accelerates therapeutic development, dramatically improves medical diagnostics, and makes personalized and predictive medicine a reality. The extraordinary team at Nautilus represents a wide spectrum of disciplines and expertise, including: protein chemists, chip designers, molecular biologists, data scientists, material scientists, biophysicists, optical engineers, microfluidics engineers, bioinformaticists, software engineers, and more. Nautilus is positioned to revolutionize proteomics, transform the way drugs are developed, and significantly improve the way human health is managed.
Verified activity
Signals from Nautilus Biotechnology
7 published signals
Products & Services
Nautilus Biotechnology released a second video series featuring Zhengjian Zhang, Ph.D., on the Nautilus Voyager™ Platform for extracting and analyzing tau proteoforms.
Reported by Nautilus Biotechnology
Research & Knowledge
Nautilus Biotechnology published a Nature Methods paper on proteoform analysis and tau proteoform analysis.
Reported by Nautilus Biotechnology
Research & Knowledge
Nautilus Biotechnology published a paper demonstrating the large-scale single-molecule analysis of tau proteoforms by Iterative Mapping in Nature Methods.
Reported by Nautilus Biotechnology
Research & Knowledge
Nautilus Biotechnology published research on the large-scale, single-molecule analysis of tau proteoforms in Nature Methods.
Reported by Jamie Rose Kuhar, Ph.D.
Research & Knowledge
Nautilus Biotechnology published a study in Nature Methods on the large-scale, single-molecule analysis of tau proteoforms.
Reported by Sheri Wilcox
Presence & Recognition
Nautilus Biotechnology is attending HUPO 2026 in Singapore from September 27 to October 1, 2026, to share how researchers use the Nautilus Voyager Platform to explore biological mechanisms with single-molecule precision and functional clarity.
Reported by Nautilus Biotechnology
Presence & Recognition
Nautilus Biotechnology Co-Founder and Chief Scientist Parag Mallick will speak at the Stanford Proteomics Users Group meeting on September 10th at 1:30pm PT about enabling quantitative proteoform analysis with a novel single-molecule proteomics analysis platform.
Reported by Nautilus Biotechnology